Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-7051 in mCRPC
NCT04575766Phase 1Terminated
- Sponsor
- Novo Nordisk
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pocenbrodib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novo Nordisk. Primary endpoints: Incidence of dose limiting toxicities at 4 weeks, Serious adverse events and clinically relevant adverse events at 26 weeks and 1 more. Started Dec 2020; status: terminated.
02
Drugs
pocenbrodib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04575766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575766.